Rein Therapeutics Stock Performance
| RNTX Stock | 1.22 0.01 0.81% |
The company holds a Beta of 1.68, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rein Therapeutics will likely underperform. Rein Therapeutics right now holds a risk of 6.09%. Please check Rein Therapeutics downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to decide if Rein Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Over the last 90 days Rein Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Rein Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:20 | Last Split Date 2022-11-11 |
1 | Rein Therapeutics Inc. stock retracement recovery analysis - July 2025 Technicals Technical Pattern Alert System - newser.com | 10/29/2025 |
2 | Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis | 11/03/2025 |
3 | Comparing Rein Therapeutics Inc. in custom built stock radars - Quarterly Performance Summary Fast Entry and Exit Trade Plans - newser.com | 11/07/2025 |
4 | How Rein Therapeutics Inc. stock reacts to bond yields - 2025 Buyback Activity Weekly Chart Analysis and Guides - newser.com | 11/12/2025 |
5 | Will Rein Therapeutics Inc. stock outperform Nasdaq index - Portfolio Risk Summary Weekly Breakout Watchlists - newser.com | 11/19/2025 |
6 | Wall Street Zen Upgrades Rein Therapeutics to Hold | 12/08/2025 |
7 | Is Rein Therapeutics Inc. stock a good choice for value investors - 2025 Market Overview Fast Gain Stock Trading Tips - DonanmHaber | 12/19/2025 |
8 | Is Rein Therapeutics Inc. stock undervalued vs historical averages - July 2025 Summary Expert-Curated Trade Recommendations - ulpravda.ru | 01/08/2026 |
Rein Therapeutics Relative Risk vs. Return Landscape
If you would invest 132.00 in Rein Therapeutics on October 11, 2025 and sell it today you would lose (10.00) from holding Rein Therapeutics or give up 7.58% of portfolio value over 90 days. Rein Therapeutics is currently generating 0.0543% in daily expected returns and assumes 6.0912% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Rein, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rein Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rein Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rein Therapeutics, and traders can use it to determine the average amount a Rein Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0089
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | RNTX | Huge Risk |
| Negative Returns |
Based on monthly moving average Rein Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rein Therapeutics by adding Rein Therapeutics to a well-diversified portfolio.
Rein Therapeutics Fundamentals Growth
Rein Stock prices reflect investors' perceptions of the future prospects and financial health of Rein Therapeutics, and Rein Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rein Stock performance.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 15.07 M | ||||
| Shares Outstanding | 26.29 M | ||||
| Price To Book | 27.28 X | ||||
| EBITDA | (28.05 M) | ||||
| Net Income | (62.88 M) | ||||
| Total Debt | 14.85 M | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (22.29 M) | ||||
| Earnings Per Share | (2.94) X | ||||
| Market Capitalization | 32.33 M | ||||
| Total Asset | 69.24 M | ||||
| Retained Earnings | (351.4 M) | ||||
| Working Capital | 7.91 M | ||||
About Rein Therapeutics Performance
Evaluating Rein Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Rein Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rein Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.29) | (5.03) | |
| Return On Capital Employed | (1.33) | (1.26) | |
| Return On Assets | (1.16) | (1.10) | |
| Return On Equity | (1.33) | (1.26) |
Things to note about Rein Therapeutics performance evaluation
Checking the ongoing alerts about Rein Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rein Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rein Therapeutics had very high historical volatility over the last 90 days | |
| Rein Therapeutics may become a speculative penny stock | |
| Rein Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Rein Therapeutics was previously known as ALRN Old and was traded on NASDAQ Exchange under the symbol ALRN. | |
| Net Loss for the year was (62.88 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rein Therapeutics generates negative cash flow from operations | |
| Latest headline from news.google.com: Is Rein Therapeutics Inc. stock undervalued vs historical averages - July 2025 Summary Expert-Curated Trade Recommendations - ulpravda.ru |
- Analyzing Rein Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rein Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rein Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rein Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rein Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rein Therapeutics' stock. These opinions can provide insight into Rein Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rein Stock Analysis
When running Rein Therapeutics' price analysis, check to measure Rein Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rein Therapeutics is operating at the current time. Most of Rein Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rein Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rein Therapeutics' price. Additionally, you may evaluate how the addition of Rein Therapeutics to your portfolios can decrease your overall portfolio volatility.